Dr. Ka Ho Gary Ho
My Social Links

Dr. Ka Ho Gary Ho

Analytical Development Scientist
Piramal Pharma Solutions, Grangemouth, Scotland

Highest Degree
Ph.D. in Pharmacology from Strathclyde University, UK

Share this Profile

Area of Interest:

Pharmacology and Toxicology
100%
Molecular Pharamcology
62%
Toxicology
90%
Biomedical Sciences
75%
Biomarkers
55%

Research Publications in Numbers

Books
0
Chapters
0
Articles
0
Abstracts
0

Selected Publications

  1. Ng, P.Y., K. McIntosh, K.H. Ho, A. Paul and R. Plevin, 2017. Purinergic P2Y11 mediated inhibition of interleukin-1β stimulated c-Jun N-terminal kinase activity in primary cultures of human endothelial cells. Eur. J. Pharmacol., (In Press). .
  2. McIntosh, K., R. Scott, K.H. Ho, A. Paul and R. Plevin, 2017. The therapeutic potential of regulating Inhibitory kappa B kinase alpha (IKKα) in prostate cancer. Patent Applic. (In Press). .
  3. Anthony, N.G., J. Baiget, G. Berretta, M. Boyd and D. Breen et al., 2017. Inhibitory Kappa B kinase α (IKKα) inhibitors that recapitulate their selectivity in cells against isoform-related biomarkers. J. Med. Chem., 60: 7043-7066.
    CrossRef  |  Direct Link  |  
  4. Gamble, C., K. McIntosh, R. Scott, K.H. Ho, R. Plevin and A. Paul, 2012. Inhibitory kappa B Kinases as targets for pharmacological regulation. Br. J. Pharmacol., 165: 802-819.
    CrossRef  |  Direct Link  |